Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 7/20 | 0.57 |
| ▸ | XDH | P47989 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1776690 | 0.89 | AR (0.57) | ARXDHMAPTALDH1A1L3MBTL1 | |
| SCHEMBL12180531 | 0.86 | ALDH1A1 (0.51) | ARXDHMAPTALDH1A1HPGD | |
| SCHEMBL14228267 | 0.84 | ALDH1A1 (0.57) | ARXDHALDH1A1HPGD | |
| SCHEMBL12433115 | 0.82 | ALDH1A1 (0.66) | ARMAPTALDH1A1HPGD | |
| SCHEMBL16958264 | 0.81 | MAPT (0.44) | ARMAPTALDH1A1L3MBTL1HPGD | |
| SCHEMBL14026553 | 0.81 | NPC1 (0.50) | MAPTALDH1A1L3MBTL1HPGDPOLB | |
| SCHEMBL13182575 | 0.81 | XDH (0.53) | XDHSLC22A12 | |
| SCHEMBL17708372 | 0.81 | ALDH1A1 (0.47) | ARXDHALDH1A1HPGD | |
| SCHEMBL15337643 | 0.81 | AR (0.47) | ARMAPTALDH1A1L3MBTL1HPGD | |
| SCHEMBL392560 | 0.80 | MAOB (0.47) | ARXDHALDH1A1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| US-8003625-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20100137254-A1 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | IMMUNOGENESIS, INC. | 2010-06-03 | — | — | US | disclosed |
| US-7666869-B2 | to provide an aliphatic nitrogen-containing 5-membered ring compound represented by the formula [I]:** Image-1wherein symbols in the formula have the following meanings;A: CH2 or S , antidiabetic agents | MITSUBISHI TANABE PHARMA CORP. (JP) | 2010-02-23 | — | — | US | disclosed |
| US-7528140-B2 | Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors | TEIJIN LIMITED (JP) | 2009-05-05 | — | — | US | disclosed |
| US-7528140-B2 | Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors | TEIJIN LIMITED (JP) | 2009-05-05 | — | — | US | disclosed |
| US-20080153821-A1 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. | 2008-06-26 | — | — | US | disclosed |
| EP-1463501-B1 | CIS-IMIDAZOLINES AS MDM2 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-06-11 | — | — | EP | disclosed |
| US-7332487-B2 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2008-02-19 | — | — | US | disclosed |
| EP-1463501-A1 | CIS-IMIDAZOLINES AS MDM2 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2004-10-06 | — | — | EP | disclosed |
| US-6617346-B1 | Inhibit the interaction of MDM2 protein with a p53-like peptide and have antiproliferative activity | HOFFMANN-LA ROCHE INC. | 2003-09-09 | — | — | US | disclosed |
| WO-2003051360-A1 | CIS-IMIDAZOLINES AS MDM2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137254-A1 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | TYMP, PAICS, PNP | AR 1595/4885XDH 4679/4885MAPT 4106/4885 |
| US-20080153821-A1 | Nitrogen-containing 5-membered ring compound | ALK, SCO2, NPR1 | AR 539/4885XDH 477/4885MAPT 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.